Watson to establish new R&D Technology Center
Watson Pharmaceuticals has announced plans to establish a Global R&D Technology Center in North Brunswick, New Jersey, US.
The company plans to retrofit 19,000sqft of space for product development and analytical laboratories. The remaining 13,000sqft will accommodate future expansion.
Watson Pharmaceuticals intends to initially invest approximately $4.5m in outfitting the new facility.
The facility is expected to employ approximately 50 scientists, chemists, engineers and support staff.
Watson president and CEO Paul Bisaro said the location of new Global R&D Technology Center will enable Watson to leverage their proximity to such educational centers of excellence as Rutgers University.
Related Insight
Suppliers Directory
Applikon Biotechnology – Advanced Bioreactor Systems
Applikon Biotechnology is a world leader in developing and supplying advanced bioreactor systems from laboratory scale to production scale for the biotech and pharmaceutical market.
Production & Manufacturing > Manufacturing > Suppliers
Sofrigam - Industrial Insulated and Refrigerated Packaging
Sofrigam designs and qualifies isothermal and refrigerated packaging enabling the transport of heat sensitive products in non-refrigerated vehicles.
Production & Manufacturing > Manufacturing > Suppliers
Glycotope - GlycoEngineering and Immunotherapeutics
Founded in 2001, Glycotope is a leading biopharmaceutical company in the fields of glycomics and immunotherapeutics that has developed a unique and regulatory approved platform technology for the development and production of NBEs and improved second generation biopharmaceuticals / BioBetters.
Production & Manufacturing > Manufacturing > Suppliers
FeF Chemicals - Manufacturer and Supplier of Benzalkonium Chloride
FeF Chemicals A/S manufactures and supplies Quaternary Ammonium Compounds (Quats), including Benzalkonium Chloride, for pharmaceutical and personal care products. FeF Chemicals also supplies Insulin for use in cell growth media. FeF Chemicals is a fully owned subsidiary of Novo Nordisk A/S, a Danish healthcare company and world leader in diabetes care.
Production & Manufacturing > Manufacturing > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Manufacturing Intelligence
Cost Savings with the DisiTest 50 Disintegration Tester
Published by Dr Schleuniger Pharmatron
Production & Manufacturing > Manufacturing > White Papers
Dual Ion Source DUIS-2020 for Simultaneous ESI and APCI Measurement
Published by Shimadzu PBR
Production & Manufacturing > Manufacturing > White Papers
GRACO's New 1590 & 3150 Pumps
Published by GRACO PBR
Production & Manufacturing > Manufacturing > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.